| Dr Bruce Henry Culver, MD | |
|
1959 Ne Pacific St, Seattle, WA 98195-0001 | |
| (206) 685-8945 | |
| (206) 685-8673 |
| Full Name | Dr Bruce Henry Culver |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Pulmonary Disease |
| Location | 1959 Ne Pacific St, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093837171 | NPI | - | NPPES |
| 8218554 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 12604 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bruce Henry Culver, MD 2035 80th Ave Se, Mercer Island, WA 98040-2204 Ph: (206) 232-2043 | Dr Bruce Henry Culver, MD 1959 Ne Pacific St, Seattle, WA 98195-0001 Ph: (206) 685-8945 |
News Archive
Since its discovery in 1989, hepatitis C virus (HCV) has been recognized as a major cause of chronic liver disease worldwide. The most recent WHO estimate of the prevalence of HCV infection is 2%, representing . about 150 million people. Every year, 3–4 million new people are infected with the hepatitis C virus, of those, approximately 60–80% develop chronic hepatitis, and 30% of them progress to cirrhosis and to end-stage liver disease.
Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.
ethica Clinical Research Inc. ("ethica"), a Contract Research Organization (CRO) headquartered in Montreal, and Matrix Pharma Canada Inc. ("Matrix Pharma"), have announced the signing of an agreement, valued at CAD1.25 Million, that provides ethica with an exclusive, worldwide license to promote and use Matrix Pharma's proprietary research data analysis technology for life sciences applications, notably for the identification and optimization of biomarkers.
Roux-en-Y gastric bypass, the most common type of bariatric surgery in the United States, is currently considered the most effective therapy for morbid obesity.
› Verified 3 days ago
Sandhya Ramanathan Panch, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |